Research on neoadjuvant dual immunotherapy for advanced melanoma has shown durable survival outcomes. The treatment involves the use of immune checkpoint inhibitors, which have been studied in various clinical trials. The effectiveness and tolerability of this approach are being explored in ongoing research, with some studies focusing on specific combinations of therapies, such as nivolumab and ipilimumab.